Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-701 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-701
Tmax of ABBV-701
(β) of ABBV-701
(t1/2) of ABBV-701
AUCt of ABBV-701
AUCinf of ABBV-701
| Arm | Type | Description |
|---|---|---|
| Part 1: Group 1 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose A or placebo. |
| Part 1: Group 2 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose B or placebo. |
| Part 1: Group 3 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose C or placebo. |
| Part 1: Group 4 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose D or placebo. |
| Part 1: Group 5 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 2: Group 6 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 2: Group 7 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 3: Group 8 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose C or placebo. |
| Part 3: Group 9 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 3: Group 10 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Part 4: Group 11 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Part 4: Group 12 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-701 | DRUG | Subcutaneous |
| Placebo | DRUG | Subcutaneous |
Inclusion Criteria: * Body weight is ≥ 35 kg and BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG * Part 2 and Part 4 only:...
ABBV-701 is an investigational small molecule being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, with a single active trial evaluating its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult participants.
ABBV-701 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy volunteers.
ABBV-701 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is currently being studied in a single active Phase 1 trial involving healthy volunteers.
ABBV-701 is being evaluated in one Phase 1 clinical trial, identified as NCT06895343. This study is assessing the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending subcutaneous or intravenous doses of ABBV-701 in healthy adult Western and Asian participants.
Yes, the Phase 1 trial of ABBV-701 is randomized, double-blind, and controlled. The study, NCT06895343, is enrolling 100 healthy adult participants in the United States and is currently active but not recruiting.